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ABSTRACT
Background Patients with cancer are particularly 
susceptible to SARS- CoV-2 infection. The systemic 
inflammatory response is a pathogenic mechanism shared 
by cancer progression and COVID-19. We investigated 
systemic inflammation as a driver of severity and 
mortality from COVID-19, evaluating the prognostic role 
of commonly used inflammatory indices in SARS- CoV-
2- infected patients with cancer accrued to the OnCovid 
study.
Methods In a multicenter cohort of SARS- CoV-2- 
infected patients with cancer in Europe, we evaluated 
dynamic changes in neutrophil:lymphocyte ratio (NLR); 
platelet:lymphocyte ratio (PLR); Prognostic Nutritional 
Index (PNI), renamed the OnCovid Inflammatory Score 
(OIS); modified Glasgow Prognostic Score (mGPS); 
and Prognostic Index (PI) in relation to oncological and 
COVID-19 infection features, testing their prognostic 
potential in independent training (n=529) and validation 
(n=542) sets.
Results We evaluated 1071 eligible patients, of 
which 625 (58.3%) were men, and 420 were patients 
with malignancy in advanced stage (39.2%), most 
commonly genitourinary (n=216, 20.2%). 844 (78.8%) 
had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 
complication. NLR, OIS, and mGPS worsened at COVID-19 
diagnosis compared with pre- COVID-19 measurement 
(p<0.01), recovering in survivors to pre- COVID-19 levels. 
Patients in poorer risk categories for each index except the 
PLR exhibited higher mortality rates (p<0.001) and shorter 
median overall survival in the training and validation sets 
(p<0.01). Multivariable analyses revealed the OIS to be 
most independently predictive of survival (validation set HR 
2.48, 95% CI 1.47 to 4.20, p=0.001; adjusted concordance 
index score 0.611).
Conclusions Systemic inflammation is a validated 
prognostic domain in SARS- CoV-2- infected patients 
with cancer and can be used as a bedside predictor of 
adverse outcome. Lymphocytopenia and hypoalbuminemia 
as computed by the OIS are independently predictive 
of severe COVID-19, supporting their use for risk 
stratification. Reversal of the COVID-19- induced 
proinflammatory state is a putative therapeutic strategy in 
patients with cancer.
INTRODUCTION
SARS- CoV-2 is the novel Betacoronavirus first 
identified in Wuhan, China, that has resulted 
in over 104 million cases and more than 
two million deaths globally as of February 
3, 2021.1 2 COVID-19, the resulting disease 
from SARS- CoV-2 infection, is character-
ized by a myriad of symptoms and systemic 
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complications. Defining symptoms according to WHO 
guidelines include fever, cough, and dyspnea, along-
side a number of non- specific constitutional symptoms.3 
Complications are similarly varied and system- wide: 
complicated COVID-19 involves acute respiratory distress 
syndrome (ARDS), coagulopathy, septic shock, and acute 
kidney and cardiac injuries.1
Evolving clinical experience in the management of 
SARS- CoV-2 has confirmed that lethality from COVID-19 
is related not only to the cytopathic effect of the virus 
but also to the host’s response to infection, which leads 
to end- organ damage and mortality through ignition of 
a sustained systemic inflammatory response.4 Patients 
with severe COVID-19 display heightened blood levels 
of interleukin (IL)-6, IL-2, IL-7, IL-10, and chemokines 
such as monocyte chemoattractant protein-1, implicating 
the innate immune response in COVID-19 progres-
sion.4 Assessment of inflammatory status at the time of 
COVID-19 diagnosis may lend itself as a bedside prog-
nostic marker and novel immunological domain for ther-
apeutic targets.
Systemic inflammation is in fact a unifying mechanism 
between cancer progression and COVID-19. The acute- 
phase response (APR) is a series of coordinated immune 
and metabolic changes that the host orchestrates in 
response to potentially harmful insults. The host’s innate 
immune response is central to the coordination of the 
APR, which is linked to both infectious and non- infectious 
noxae, including cancer.5 Activation of an APR is reflected 
in the acute derangement of hematological and biochem-
ical parameters, including reactive leukocytosis, periph-
eral blood neutrophilia, lymphopenia, elevated C- reactive 
protein (CRP) levels, and hypoalbuminemia.5 6 A number 
of these laboratory parameters have been individually 
linked to worse prognosis from COVID-19.4 Inflammation- 
based indices, including the neutrophil:lymphocyte ratio 
(NLR),7 platelet:lymphocyte ratio (PLR),8 Prognostic 
Nutritional Index (PNI),9 10 modified Glasgow Prognostic 
Score (mGPS),11 and Prognostic Index (PI),12 have been 
derived from optimal integration of acute- phase reactants 
and have been consistently shown to predict for adverse 
prognosis independent of treatment, stage, and type 
of cancer. Evaluation of these indices in the context of 
SARS- CoV-2- infected patients with cancer may elucidate 
parameters of the APR that are linked to the progression 
of SARS- CoV-2 infection in its most lethal forms. We took 
special interest in the PI, which we renamed the OnCovid 
Inflammatory Score (OIS) in the context of COVID-19, as 
its calculation considers lymphopenia and hypoalbumin-
emia, two parameters individually shown to predict for 
COVID-19 prognosis.4
In a previous study, we had shown that a significant 
proportion of patients with cancer develop severe 
COVID-19 and that mortality is strongly related to host 
rather than oncological factors, including number of 
comorbidities and advancing age.13 14 However, the mech-
anisms underlying excess mortality observed in patients 
with cancer are not fully understood. In this study, we 
sought to determine whether the presence of a systemic 
inflammatory response at the time of COVID-19 diag-
nosis may help identify patients with severe SARS- CoV-2 
infection and predict outcome in this population. To 
pursue this aim, we independently validated the OIS and 
a panel of inflammation- based indices in a large reposi-
tory of patients with COVID-19 and cancer as part of the 
OnCovid study.
MATERIALS AND METHODS
Study design, patient demographics, and data collection
From the OnCovid repository, a retrospective registry of 
SARS- CoV-2- infected patients with cancer in Europe,14 we 
aimed to evaluate a panel of inflammation- based indices 
that are linked with the survival of patients with cancer 
for their prognostic role in the context of COVID-19 
diagnosis.7–9 11 12 For the purpose of this study, the 
combination of hypoalbuminemia and lymphocytopenia 
(albumin concentration (g/L)+5 × total lymphocyte count 
(109/L)), previously qualified as a nutritional predictor 
of outcome (PNI), was redefined as the OIS in view of its 
qualification as an inflammatory predictor in the context 
of COVID-19 infection. Between February 27 and June 23, 
2020, 1318 patients were consecutively referred from 23 
academic centers in the UK (n=539), Spain (n=380), Italy 
(n=374), Belgium (n=19), and Germany (n=6, (online 
supplemental table 1)). Eligibility criteria for OnCovid 
included (1) SARS- CoV-2 infection confirmed by naso-
pharyngeal swab and subsequent reverse transcriptase 
PCR (RT- PCR)15 and (2) history of solid or hematological 
malignancy at any timepoint before or during COVID-19 
disease course. Both patients with active malignancies 
and patients in cancer remission were included in the 
study. Patients were  ≥ 18 years of age, and anonymized 
electronic medical record data were entered into the 
Research Electronic Data Capture (Vanderbilt Univer-
sity) tool hosted by the Medical Statistics Unit in Novara, 
Italy,16 17 which coordinated database access and curation.
Inflammation-based indices
Eligible patients (n=1071) were stratified on the basis of 
a selected panel of five biomarkers of systemic inflamma-
tion (NLR, PLR, OIS, mGPS, and PI) at three timepoints: 
at the last oncological follow- up prior to SARS- CoV-2 
infection (pre- COVID-19), at COVID-19 diagnosis, and, 
in surviving patients, at the first oncological follow- up 
after SARS- CoV-2 infection with a documented negative 
SARS- CoV-2 swab. Calculations for each inflammation- 
based index are shown in online supplemental table 
2. Patients were stratified into good versus poor risk 
subgroups on the basis of predefined categories for 
the mGPS and PI, depending on whether they had an 
abnormal CRP and/or albumin (for mGPS) or white 
cell count (for PI) at the point of biomarker measure-
ment.11 12 For inflammatory biomarkers characterized 
by a continuous distribution, good and poor risk groups 
were identified by the median value of the distribution.
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Definitions and study endpoints
Features of severe COVID-19 such as ARDS and septic shock 
were defined according to WHO guidelines.3 Furthermore, 
all comorbid conditions, complications, and key COVID-19 
symptoms were determined from WHO guidelines.3 Reso-
lution of SARS- CoV-2 infection was confirmed via negative 
RT- PCR result following nasopharyngeal swab for surviving 
patients. Active malignancy was defined by presence of onco-
logical disease according to clinical criteria for the corre-
sponding tumor type. Patients categorized as undergoing 
active cancer therapy had received anti- cancer therapy within 
4 weeks of COVID-19 diagnosis, and patients with no treat-
ment history for cancer were categorized as treatment naïve. 
To evaluate the prognostic value of inflammation- based 
indices, we randomly divided eligible patients into training 
and validation sets. Primary study outcome was mortality. 
Overall survival (OS) was determined from the date of 
positive SARS- CoV-2 RT- PCR to the date of death or final 
follow- up.
Statistical analyses
Data following a normal distribution are presented as 
mean with SD, and data differing from normal distri-
bution are presented as median with IQR. The Mann- 
Whitney U test and the Wilcoxon signed- rank test were 
used as appropriate to compare the medians of non- 
normally distributed continuous data. Categorical vari-
ables, shown as absolute counts or percentages, were 
compared using Pearson’s χ2 test. Kaplan- Meier esti-
mates with a log- rank test were employed for univariable 
survival plot analysis. Univariable HRs were calculated 
through logistic Cox regression, and multivariable HRs 
were calculated through Cox regression with conditional 
backward elimination using a removal value of 0.10 
and entry value of 0.05. Harrell’s concordance index 
(C- index) was used to evaluate the predictive ability of 
inflammation- based indices and the multivariable model. 
150 bootstrap samples were used to calculate the 95% CI 
for each C- index, estimate the optimism due to poten-
tial overfitting, and provide optimism- adjusted C- index 
values with corresponding CIs. A two- tailed p value of <
 0.05 was considered the threshold for statistical signifi-
cance. Dataset management and statistical analyses were 
performed using Statistical Product and Service Solutions 
V.24 for Apple Macintosh OSX (IBM, Armonk, New York, 
USA). Figures were created in Prism V.8 for Apple Macin-
tosh OSX (GraphPad, San Diego, California, USA).
Patient involvement
Patients were involved via retrospective analysis of anonymized 
patient chart data. Patients did not participate in the plan-
ning of this study, and this study involved no interventions.
RESULTS
Inclusion criteria, training and validation set assortment, and 
demographics
A total of 1318 patients ≥18 years of age with a history of 
active malignancy or in cancer remission and possessing 
a positive COVID-19 diagnosis were consecutively entered 
into the main OnCovid registry. In total, 247 patients were 
excluded, leaving a final dataset of 1071 eligible patients 
(figure 1). Reasons for exclusion were (1) lack of labora-
tory data to calculate at least one biomarker of interest 
(n=154), (2) leukemia or myeloma diagnosis (n=98), and/
or (3) lack of specification of cancer type (n=2). Patients 
with leukemia and myeloma were excluded due to the 
potential confounding effect of the neoplastic derange-
ment on peripheral blood values used to compute bone 
marrow- derived inflammation indices.18–20 From this final 
study population (n=1071), patients were randomly allo-
cated into a training set (n=529) or a validation set (n=542) 
matched for age, comorbid burden, number of COVID-19 
complications, and proportion of patients with active 
malignancy (online supplemental table 3). Out of 1071 
eligible patients, the majority were male (n=625, 58.3%) 
with a mean age of 68.2 years (SD  ± 13.4, range 21–99 
years). Patient distribution across participating academic 
centers is shown in online supplemental table 1. Genito-
urinary cancers comprised the most common primary 
tumor site (n=216, 20.2%), and the majority of patients 
had evidence of active malignancy (n=687, 64.1%). At 
COVID-19 diagnosis, 519 (48.5%) patients had localized 
or locoregional disease; 420 patients (39.2%) had meta-
static/advanced disease; and 516 (48.2%) patients were 
receiving anticancer therapy. Most patients had at least 
one comorbidity (n=844, 78.8%), most commonly hyper-
tension (n=496, 46.3%) or cardiovascular disease (n=257, 
24.0%).
Presenting SARS- CoV-2 symptoms included fever 
(n=660, 61.6%) and cough (n=542, 50.6%). Of the 957 
(89.4%) patients hospitalized, 124 (13.0%) were esca-
lated to intensive or subintensive care. The majority of 
patients required supplemental oxygen therapy (n=627, 
58.5%), and a subset required mechanical ventilation 
(n=115, 10.7%). Most patients received at least one 
COVID-19- specific drug treatment (n=708, 66.1%), with 
the majority receiving an antimalarial or antiviral agent 
(n=622, 58.1%). A total of 754 (70.4%) patients devel-
oped COVID-19 complications, most frequently acute 
respiratory failure (n=627, 58.5%). At the time of data-
base censoring (June 23, 2020), 375 (35.0%) patients 
were deceased and 680 (63.5%) were discharged from 
the hospital or were in- hospital survivors (online supple-
mental table 4 highlights COVID-19 complications and 
complete patient demographics).
Systemic inflammatory response identifies patients with 
adverse outcomes
In eligible patients (n=1071), median NLR, PLR, and OIS 
at COVID-19 diagnosis were 6.1 (IQR 8.7), 270.1 (IQR 
260.6), and 38.5 (IQR 10.5) respectively. In total, 526 
(49.1%) patients had NLR ≥ 6, 491 (45.8%) had PLR ≥
 270, and 384 (35.9%) had OIS ≤ 40. mGPS was available 
in 672 (62.7%) patients at COVID-19 diagnosis, with 503 
(47.0%) patients being defined as intermediate (mGPS 
1, n=196, 18.3%) or poor risk (mGPS 2, n=307, 28.7%). 
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A total of 828 (77.3%) patients were evaluable for PI, 
with 686 (64.1%) classifying as intermediate (PI 1, n=546, 
51.0%) or poor risk (PI 2, n=140, 13.1%) subgroups.
As shown in online supplemental figure 1, OIS values 
were significantly lower in patients with active malig-
nancy (median 38.1, IQR 11.2), a factor known to predict 
for outcome from COVID-19,13 compared with patients 
in remission (median 39.5, IQR 9.6, p<0.05). Patients 
with active malignancy were also more likely to classify 
in poorer mGPS risk groups (p<0.05). A comparison of 
inflammation scores across tumor types is shown in online 
supplemental table 5.
Median NLR, PLR, and OIS at COVID-19 diagnosis 
were studied in relation to patients’ mortality along with 
the distribution of the mGPS and PI. Mortality from 
COVID-19 was associated with categorization into the 
poorer risk group for each index (p< 0.05, figure 2A).
To evaluate the relative contribution of active 
SARS- CoV-2 infection over underlying malignancy in 
determining the systemic inflammatory response, we 
evaluated dynamic changes across the pre- COVID-19, at, 
and post- COVID-19 diagnosis timepoints in a subset of 
SARS- CoV-2 survivors (n=65, 6.1%). All samples taken at 
post- COVID-19 diagnosis were defined as measurements 
taken during the first outpatient oncological follow- up 
after COVID-19 with a negative SARS- CoV-2 swab at the 
moment of blood sampling. Patients had data for all 
indices (NLR, n=55; PLR, n=50; OIS, n=23; mGPS, n=8; 
and PI, n=13). The mean interval between pre- COVID-19 
and at COVID-19 diagnosis timepoints was 270 days 
(SD±855), and the mean interval between COVID-19 
diagnosis and post- COVID-19 diagnosis timepoints was 39 
days (SD±24).
As shown in figure 2B, NLR values were significantly 
higher at COVID-19 diagnosis (median 6.1, IQR 8.7) 
compared with pre- COVID-19 (median 2.9, IQR 3.1, p<
 0.001) and post- COVID-19 timepoints (median 2.6, IQR 
2.8, p< 0.01), whereas pre- COVID and post- COVID-19 
values did not differ (p=0.82). Similar dynamic changes 
were described for the OIS, which appeared lower at 
COVID-19 diagnosis (median 38.5, IQR 10.5) compared 
with pre- COVID-19 (median 47.0, IQR 9.6, p< 0.001) and 
post- COVID-19 timepoints (47.8, IQR 10.0, p< 0.0001), 
with no difference noted between pre- COVID-19 and 
post- COVID-19 measurements (p=0.58). mGPS and PI 
distribution also varied across timepoints (figure 2B).
Next, we sought to determine the relationship between 
patients’ inflammatory scores at COVID-19 diagnosis 
and previously established predictors of mortality or 
disease severity.13 21–24 As shown in online supplemental 
table 6, patients in the poor risk groups for all inflam-
matory indices developed a greater number of COVID-19 
Figure 1 Patient disposition. mGPS, modified Glasgow Prognostic Score; NLR, neutrophil:lymphocyte ratio; OIS, OnCovid 
Inflammatory Score; PI, Prognostic Index; PLR, platelet:lymphocyte ratio.
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complications. Furthermore, patients in poor risk groups 
for all indices except the PLR were older and had a higher 
comorbid burden. Patients in poor risk categories for the 
NLR, mGPS, and PI were less likely to be undergoing 
anticancer therapy at COVID-19 diagnosis and were more 
often male (online supplemental table 6).
We also investigated the association between inflamma-
tory markers and laboratory variables known to predict 
for increased mortality from COVID-19.21–24 As shown in 
online supplemental figure 2, an NLR of ≥6 was associated 
with increased lactate dehydrogenase (LDH, p< 0.0001), 
D- dimer (p< 0.01), troponin (p<0.001), and ferritin 
(p<0.01) levels compared with an NLR<6. An OIS ≤ 40 was 
associated with heightened LDH (p< 0.001), D- dimer (p<
 0.001), and ferritin (p< 0.001) levels. Poor risk mGPS and 
PI categories also exhibited an association with clinical 
variables.
OIS predicts for decreased OS and greater risk of severe 
COVID-19 in patients with cancer
To accurately evaluate the prognostic performance of 
inflammation- based indices, we randomly assigned the 
1071 eligible patients into a training (n=529) and valida-
tion set (n=542, figure 1). Both datasets were matched for 
key characteristics that are known to influence prognosis 
from COVID-19, including age ≥65 years, number of 
comorbidities, number of COVID-19 complications, and 
presence of active malignancy (online supplemental table 
3).13 Table 1 presents complete demographics of both the 
training and validation sets. Unadjusted mortality rates 
were similar across datasets (36.1% in the training set and 
35.0% in the validation set, p=0.16).
In the training set, all tested inflammatory indices but 
the PLR were associated with unadjusted mortality rates 
(p<0.0001), as shown in figure 3A. Analysis of unadjusted 
mortality in the validation set confirmed these findings 
(figure 3B). Patients with NLR of  ≥ 6, OIS of  ≤ 40, and 
poor risk mGPS and PI values had shorter median OS (p<
 0.001, figure 4 and online supplemental table 7). Addi-
tionally, as shown in table 2, patients in poor risk groups 
for all inflammatory indices except the PLR (p=0.55) 
presented univariable HRs above 1.00 (p≤0.001). This was 
confirmed in the validation set analysis (p<0.01; figure 5, 
table 2 and online supplemental table 7).
In multivariable Cox regression models, the inflamma-
tory indices were evaluated for their independent prog-
nostic ability against established prognostic factors for 
Figure 2 Relationship between inflammatory markers and COVID-19 outcomes and marker values at timepoints. (A) Median 
inflammatory index values or distributions at COVID-19 diagnosis in living versus deceased patients for the NLR (n=661 alive, 
n=360 dead; p< 0.0001), PLR (n=628 alive, 338 dead; p< 0.05), OIS (n=413 alive, n=230 dead; p< 0.0001), mGPS (n=430 alive, 
n=229 dead; p< 0.0001), and PI (n=525 alive, n=295 dead; p< 0.0001). (B) Median values and distributions across timepoints for 
the NLR (n=55), PLR (n=50), OIS (n=23), mGPS (n=143 pre- COVID-19, n=672 at diagnosis, n=32 post- COVID-19), and PI (n=163 
pre- COVID-19, n=828 at diagnosis, n=36 post- COVID-19). *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001. Error bars represent 
95% CIs from the median. mGPS, modified Glasgow Prognostic Score; NLR, neutrophil:lymphocyte ratio; ns, not significant; 
OIS, OnCovid Inflammatory Score; PI, Prognostic Index; PLR, platelet:lymphocyte ratio.
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Table 1 Patient demographics of training and validation 







Age (years), mean±SD 67.9±13.3 68.5±13.5
Age 65 years, n (%) 311 (58.8) 334 (61.6)
Sex, n (%)
  Male 296 (56.0) 329 (60.7)
  Female 231 (43.7) 212 (39.1)
  Information 
unavailable
2 (0.3) 1 (0.2)
Smoking history, n (%)
  Never smoker 205 (38.8) 207 (38.2)
  Current/former 
smoker
228 (43.1) 234 (43.2)
  Unknown 96 (18.1) 101 (18.6)
Cancer type, n (%)
  Head and neck 22 (4.2) 12 (2.2)
  Lung and thoracic 67 (12.7) 87 (16.1)
  Gastroesophageal 30 (5.7) 22 (4.1)
  Hepatobiliary 33 (6.2) 22 (4.1)
  Duodenal and lower 
GI tract
61 (11.5) 71 (13.1)
  Breast 85 (16.1) 92 (17.0)
  Gynecological 35 (6.6) 22 (4.1)
  Genitourinary 108 (20.4) 108 (19.9)
  Skin 17 (3.2) 26 (4.8)
  Lymphoma 49 (9.3) 38 (7.0)
  Other 22 (4.1) 42 (7.6)
Tumor stage, n (%)
  Localized 173 (32.7) 187 (34.5)
  Locoregional 72 (13.6) 87 (16.1)
  Metastatic 223 (42.2) 197 (36.3)
  Information 
unavailable
61 (11.5) 71 (13.1)
Tumor status at COVID-19 diagnosis, n (%)
  Active malignancy 353 (66.7) 334 (61.6)
  Remission 150 (28.4) 182 (33.6)
  Information 
unavailable
26 (4.9) 26 (4.8)
Ongoing anticancer 
therapy at COVID-19 
diagnosis, n (%)
264 (49.9) 252 (46.5)
Prior radical therapies, 
n (%)
285 (53.9) 306 (56.5)
  Surgery 244 (46.1) 266 (49.0)
  Adjuvant/neoadjuvant 
chemotherapy







Prior palliative systemic 
therapy, n (%)
147 (27.8) 130 (24.0)
  Chemotherapy 97 (18.3) 87 (16.1)
  Immunotherapy 21 (4.0) 25 (4.6)
  Endocrine therapy 29 (5.5) 24 (4.4)
  Targeted therapy 22 (4.2) 23 (4.2)
Prior curative systemic 
therapy, n (%)
32 (6.0) 30 (5.5)
Prior radiotherapy, n (%) 150 (28.4) 169 (31.2)
Prior lines of palliative therapy, n (%)
  1 75 (14.2) 60 (11.1)
  2 30 (5.7) 29 (5.4)
  3 33 (6.2) 28 (5.2)
Comorbidities, n (%) 425 (80.3) 419 (77.3)
  Hypertension 251 (47.4) 245 (45.2)
  Diabetes 115 (21.7) 123 (22.7)
  Cardiovascular 
disease
128 (24.2) 129 (23.8)
  Chronic pulmonary 
disease
80 (15.1) 80 (14.8)
  Chronic kidney 
disease
62 (11.7) 63 (11.6)
  Cerebrovascular 
disease
37 (7.0) 41 (7.6)
  Dementia 27 (5.1) 36 (6.6)
  Peripheral vascular 
disease
19 (3.6) 21 (3.9)
  Liver impairment 11 (2.1) 10 (1.8)
  Immunosuppression 16 (3.0) 29 (5.4)
  Steroid therapy in 
progress
23 (4.3) 27 (5.0)
  Other 164 (31.0) 144 (26.6)
Number of comorbidities (%)
  0 104 (19.7) 123 (22.7)
  1 149 (28.2) 149 (27.5)
  2 129 (24.4) 118 (21.8)
  3 147 (27.7) 152 (28.0)
COVID-19 symptoms at 
diagnosis, n (%)
497 (94.0) 514 (94.8)
  Fever 317 (59.9) 343 (63.3)
  Cough 257 (48.6) 285 (52.6)
  Dyspnea 206 (38.9) 232 (42.8)
  Fatigue 132 (25.0) 125 (23.1)
  Myalgia 60 (11.3) 57 (10.5)
  Diarrhea 50 (9.5) 76 (14.0)
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COVID-19.13 21–24 In the training set analysis, the OIS was 
the only factor emerging as significantly prognostic with 
patients in the poor risk group (OIS≤40) presenting a 
multivariable HR of 1.97 (95% CI 1.19 to 3.26, p=0.008; 
table 2). The independent prognostic value of the OIS 
also emerged in multivariable analyses of the validation 
set (OIS≤40, HR 2.48, 95% CI 1.47 to 4.20, p=0.001; 
table 2), confirming its external validity as a prognostic 
factor for COVID-19. Analysis of inflammatory indices for 
prognostic ability was further evaluated through calcula-
tion of Harrell’s C- index (online supplemental table 8). 
The mGPS (optimism- adjusted C- index 0.634, 95% CI 
0.595 to 0.680) and OIS (adjusted C- index 0.603, 95% CI 
0.555 to 0.646) emerged as most predictive in the training 
set. OIS was most predictive in validation set analysis 
(adjusted C- index 0.611, 95% CI 0.564 to 0.668) followed 
by the mGPS (adjusted C- index 0.596, 95% CI 0.548 to 
0.651; online supplemental table 8).
DISCUSSION
Previous work has emphasized the contribution of 
comorbid burden, advanced age, and a diagnosis of 
hematological malignancy as risk factors for mortality 
from COVID-19; however, the molecular and immunolog-
ical mechanisms that lead to a more adverse COVID-19 
course in patients with cancer are largely unknown.13 25
In our study, we demonstrate that the presence of a 
proinflammatory diathesis as measured by the NLR, OIS, 
mGPS and PI is generally associated with worsening levels 
of established biomarkers of COVID-19 severity such as 
higher circulating D- dimer, troponin, ferritin and LDH 
concentration and less strongly related to the presence of 
measurable or active malignancy. These findings, paired 
with evidence of dynamic changes of inflammatory 
markers, strengthen the link between systemic inflamma-
tion as a SARS- CoV-2- driven disease mechanism linked 
with adverse clinical outcome.
Interestingly, activation of a systemic inflammatory 
response appears unevenly distributed across tumor 
sites. Patients with breast cancer, for instance, had lower 
mortality in our study (20.9%) and were more likely to 
cluster within better risk categories according to inflam-






  Nausea or vomiting 33 (6.2) 47 (8.7)
  Sore throat 18 (3.4) 9 (1.7)
  Headache 21 (4.0) 21 (3.9)
  Dysgeusia 14 (2.6) 21 (3.9)
  Anosmia 13 (2.5) 16 (3.0)
  Other (ie, confusion 
and delirium)
119 (22.5) 124 (22.9)
Number of symptoms at diagnosis (%)
  0 32 (6.0) 28 (5.2)
  1 125 (23.6) 104 (19.2)
  2 151 (28.5) 149 (27.5)
  3 221 (41.9) 261 (48.2)
Hospitalization rate, n 
(%)
477 (90.2) 480 (88.6)
Admission to intensive 
or subintensive care 
unit, n (%)
59/477 (12.4) 65/480 (13.5)
COVID-19- specific drug 
treatments, n (%)
349 (66.0) 359 (66.2)
  Antibiotics 294 (55.6) 301 (55.5)
  Hydroxychloroquine 
or chloroquine
199 (37.6) 193 (35.6)
  Lopinavir/ritonavir 86 (16.3) 86 (15.9)
  Systemic 
corticosteroids
45 (8.5) 46 (8.5)
  Remdesivir 5 (0.9) 7 (1.3)
  Tocilizumab 18 (3.4) 28 (5.2)




309 (58.4) 323 (59.6)
  Oxygen therapy 307 (58.0) 320 (59.0)
  Mechanical ventilation 44 (8.3) 71 (13.1)
COVID-19 
complications, n (%)
372 (70.3) 382 (70.5)
  Acute respiratory 
failure
307 (58.0) 320 (59.0)
  ARDS 61 (11.5) 70 (12.9)
  Acute kidney injury 42 (7.9) 44 (8.1)
  Secondary infection 49 (9.3) 37 (6.8)
  Sepsis 29 (5.5) 23 (4.2)
  Septic shock 22 (4.2) 23 (4.2)
  Acute cardiac injury 12 (2.3) 12 (2.2)
  Acute liver injury 4 (0.8) 6 (1.1)
  Others (ie, DIC) 33 (6.2) 28 (5.2)
Number of complications (%)








  1 190 (35.9) 204 (37.6)
  2 101 (19.1) 93 (17.2)
  3 42 (7.9) 47 (8.7)
  Information 
unavailable
39 (7.4) 38 (7.0)
ARDS, acute respiratory distress syndrome; DIC, disseminated 
intravascular coagulation; GI, gastrointestinal.
Table 1 Continued
 on A
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inflammatory scores and mortality in selected tumors 
such as breast cancer is highly provocative and warrants 
further research into whether certain tumor types are 
associated with a more favorable immune response to 
COVID-19.
Irrespective of tumor- specific considerations, analysis of 
survival confirms the NLR, OIS, mGPS, and PI as tumor- 
agnostic predictors of OS in both the training and valida-
tion sets, strengthening the external validity of the APR 
as a driver of mortality from COVID-19. In our study, the 
PLR did not emerge as a predictor of survival, suggesting 
reactive thrombocytosis as a suboptimal marker to iden-
tify severe COVID-19. This is perhaps unsurprising given 
that thrombocytopenia, rather than thrombocytosis, has 
been implicated in severe COVID-19.26 27
Our study shows that the systemic inflammatory response 
in patients with cancer diagnosed with COVID-19 is influ-
enced by advanced age and comorbid burden. A number 
of studies have reproducibly shown these features to 
predict for adverse clinical course in SARS- CoV-2- infected 
patients irrespective of a diagnosis of cancer.13 21–24 Our 
data contribute to shed light on this relationship by high-
lighting that these categories at risk are more likely to 
mount an exaggerated innate response to SARS- CoV-2 as 
evidenced by significantly worse derangement biomarkers 
of systemic inflammation in these subgroups, tracing an 
important link between the extent of such proinflamma-
tory response and outcome in these high- risk categories.
Because the panel of proinflammatory markers we 
studied relies on diverse and often non- redundant acute- 
phase reactants (hypoalbuminemia and neutrophilia) an 
important aim of our study was to establish the prognostic 
accuracy of each score in predicting patients’ OS.
We therefore tested the inflammatory indices in multi-
variable models including age, comorbid burden, and 
sex. We confirmed the combination of hypoalbuminemia 
and lymphopenia as computed by the OIS as a strong, 
independent predictor of survival, leading us to opti-
mally select proinflammatory features that best scale with 
outcome in the context of COVID-19 and cancer. Both 
lymphopenia and hypoalbuminemia have previously been 
identified as independent prognostic factors in patients 
affected by COVID-19 without cancer.27 28 Our study shows 
that combination of these traits optimally scales with the 
prognosis of SARS- CoV-2- infected patients with cancer, an 
approach that was not considered in previous studies.
Taken together, our results qualify the OIS in SARS- 
CoV-2- infected patients with cancer as a readily available, 
inexpensive, and validated predictor of outcome in this 
patient population characterized by high risk of mortality 
following infection with SARS- CoV-2. The independence 
of and tumor- agnostic value of the OIS yields potential 
promise as a source of therapeutic targets to modulate 
innate immunity and prevent end- organ damage and 
COVID-19- related mortality in patients with cancer.
Our study acknowledges a number of limitations. 
The retrospective study design is a limitation shared 
by a number of studies published in this area29–31 and 
contributes to heterogeneity in treatment decisions, 
including escalation to intensive/high- dependence 
care and missing outcome data. Furthermore, non- 
cancer controls would have helped us understand 
Figure 3 Relationship between inflammatory markers and unadjusted mortality. Inflammatory marker values at COVID-19 
diagnosis divided into good and poor risk groups plotted against unadjusted mortality rates for the (A) training set and (B) 
validation set. Error bars represent lower and upper limits. ***P<0.001, ****P<0.0001. mGPS, modified Glasgow Prognostic 
Score; NLR, neutrophil:lymphocyte ratio; ns, not significant; OIS, OnCovid Inflammatory Score; PI, Prognostic Index; PLR, 
platelet:lymphocyte ratio.
 on A
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whether the impact of proinflammatory scores is 
similar in patients who do not have cancer. Addition-
ally, our study included only patients with confirmed 
SARS- CoV-2 infection determined by RT- PCR, leaving 
us no information on immune dysfunction in asymp-
tomatic carriers. Finally, the 270- day gap between pre- 
COVID-19 and at COVID-19 diagnosis inflammatory 
index calculations for patients with pre- COVID-19, at, 
and post- COVID-19 diagnosis information available is 
a study limitation as is the smaller size of this 65- patient 
cohort.
Despite the acknowledged limitations, our study is the 
largest to attempt a robust and standardized evaluation 
of novel biomarkers of outcome in SARS- CoV-2- infected 
patients with cancer. The geographical diversity of our 
patient population and the choice of external validation 
limit the risk of overfitting of our survival estimates and 
facilitate a broader generalizability of our results.
Figure 4 Univariable survival analysis of inflammatory markers (training set). Kaplan- Meier estimates for univariable survival 
analysis are shown for the NLR (n=447, p< 0.001), OIS (n=273, p< 0.0001), mGPS (n=278, p< 0.0001), and PI (n=361, p< 0.0001) 
at COVID-19 diagnosis with significance calculated following log- rank methodology. ***P< 0.001, ****P< 0.0001. mGPS, modified 
Glasgow Prognostic Score; NLR, neutrophil:lymphocyte ratio; OIS, OnCovid Inflammatory Score; PI, Prognostic Index.
 on A
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In conclusion, we have demonstrated that the systemic 
inflammatory response can be used not only to facilitate 
an individualized risk assessment of patients’ mortality 
but also to better understand the disease biology of 
SARS- CoV-2 infection. Our work ties a dysfunctional proin-
flammatory response to poorer outcomes from COVID-19 
in cancer and validates the combination of lymphopenia 
and hypoalbuminemia as measured by the OIS as a tumor- 
agnostic predictor of mortality following adjustment for 
key clinicopathological features, including comorbid 
burden and age. In the clinic, patients presenting with 
an OIS below 40 at COVID-19 diagnosis should be consid-
ered at higher risk of adverse outcome by treating physi-
cians. Future study of the OIS in patients without cancer is 
warranted to validate its utility as a predictor of outcome 
in the general population. Our findings provide a clinical 
rationale for therapeutic targeting of the inflammatory 
response in SARS- CoV-2- infected patients with cancer.
Figure 5 Univariable survival analysis of inflammatory markers (validation set). Kaplan- Meier estimates for univariable survival 
analysis are shown for the NLR (n=452, p< 0.0001), OIS (n=272, p< 0.0001), mGPS (n=291, p< 0.001), and PI (n=384, p< 0.01) at 
COVID-19 diagnosis with significance calculated following log- rank methodology. **P< 0.01, ***P< 0.001, ****P< 0.0001. mGPS, 
modified Glasgow Prognostic Score; NLR, neutrophil:lymphocyte ratio; OIS, OnCovid Inflammatory Score; PI, Prognostic Index.
 on A
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